Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Piyachat Roopngam, Kewei Liu, Lin Mei, Yi Zheng, Xianbing Zhu, Hsiang-I Tsai & Laiqiang Huang. (2016) Hepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response. International Journal of Nanomedicine 11, pages 5361-5370.
Read now
Read now
W. Mei Kok. (2016) New developments in flavivirus drug discovery. Expert Opinion on Drug Discovery 11:5, pages 433-445.
Read now
Read now
KR Jyothi, Jagadish Beloor, Ara Jo, Minh Nam Nguyen, Tae Gyu Choi, Jin-Hwan Kim, Salima Akter, Sang-Kyung Lee, Chi Hoon Maeng, Hyung Hwan Baik, Insug Kang, Joohun Ha & Sung Soo Kim. (2015) Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. International Journal of Nanomedicine 10, pages 903-921.
Read now
Read now
Syed-Mohammed Jafri & Stuart C. Gordon. (2015) The safety of daclatasvir for the treatment of hepatitis C. Expert Opinion on Drug Safety 14:11, pages 1787-1797.
Read now
Read now
Articles from other publishers (9)
C. Nelson Hayes, Michio Imamura, Junko Tanaka & Kazuaki Chayama. (2022) Road to elimination of HCV: Clinical challenges in HCV management. Liver International 42:9, pages 1935-1944.
Crossref
Crossref
Xing-Yue Ji, Jin-Hua Chen, Guang-Hui Zheng, Meng-Hao Huang, Lei Zhang, Hong Yi, Jie Jin, Jian-Dong Jiang, Zong-Gen Peng & Zhuo-Rong Li. (2016)
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate
N
-Acetylgalactosaminyltransferase 1
. Journal of Medicinal Chemistry 59:22, pages 10268-10284.
Crossref
Crossref
Theo Luiz Ferraz de Souza, Sheila Maria Barbosa de Lima, Vanessa L. de Azevedo Braga, David S. Peabody, Davis Fernandes Ferreira, M. Lucia Bianconi, Andre Marco de Oliveira Gomes, Jerson Lima Silva & Andréa Cheble de Oliveira. (2016) Charge neutralization as the major factor for the assembly of nucleocapsid-like particles from C-terminal truncated hepatitis C virus core protein. PeerJ 4, pages e2670.
Crossref
Crossref
Bethany R. Baumgart, Faye Wang, Jae Kwagh, Chris Storck, Catherine Euler, Megan Fuller, Damir Simic, Suresh Sharma, Jamie J. Arnold, Craig E. Cameron, Terry R. Van Vleet, Oliver Flint, Roderick T. Bunch, Marc H. Davies, Michael J. Graziano & Thomas P. Sanderson. (2016) Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function. Toxicological Sciences 153:2, pages 396-408.
Crossref
Crossref
Bashar M Attar. (2016) Hepatitis C virus: A time for decisions. Who should be treated and when?. World Journal of Gastrointestinal Pharmacology and Therapeutics 7:1, pages 33.
Crossref
Crossref
Megha U. Lokhande, Robert Thimme, Paul Klenerman & Nasser Semmo. (2015) Methodologies for the Analysis of HCV-Specific CD4+ T Cells. Frontiers in Immunology 6.
Crossref
Crossref
Claire Gondeau. (2015) Hepatitis C virus infection: Are there still specific problems with genotype 3?. World Journal of Gastroenterology 21:42, pages 12101.
Crossref
Crossref
John P. Sabo, Benjamin Lang, Mabrouk Elgadi & Fenglei Huang. (2015) Effect of the Hepatitis C Virus Protease Inhibitor Faldaprevir on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers. Antimicrobial Agents and Chemotherapy 59:1, pages 514-519.
Crossref
Crossref
Elena Tomasello, Emeline Pollet, Thien-Phong Vu Manh, Gilles Uzé & Marc Dalod. (2014) Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. Frontiers in Immunology 5.
Crossref
Crossref